Chief Executive Officer and Director

Mr. Hendrick has been with Cetya for 8 years, serving as an advisor to Cetya for one year prior to becoming its CEO in July 2014. Prior to Cetya, Mr. Hendrick spent over 20 years working for Genzyme Corporation, most recently as the Vice President and General Manager of Early Development for the Oncology business. Mr. Hendrick worked for Integrated Genetics for six years prior to its merger with Genzyme in 1989, and in research for the Life Sciences division of Millipore Corporation for 11 years before joining Integrated Genetics and the biotechnology industry in 1983. Mr. Hendrick holds a B.S. in Life Sciences from the Massachusetts Institute of Technology and a M.B.A. from Northeastern University.

Chief Scientific Officer

Dr. Junker has worked for 30 years developing and commercializing therapeutic products for Biotechnology and Pharmaceutical companies. He served as an advisor to Cetya in 2013, VP Preclinical Development since 2014, and CSO since 2019. He was previously Consultant to Amgen, AstraZeneca, Ampio Pharmaceuticals, KBI BioPharma, and Novartis among other companies. Dr Junker was Founder and COO of Coragen Biologics from 2001 to 2004, and Director of Process Development and Engineering at Sulzer Biologics from 1996 to 2001. Dr Junker was a Postdoctoral Fellow and junior Faculty member at University of Colorado Health Sciences Center from 1986 to 1989, holds a Ph.D. from the Department of Nutritional Sciences, Purdue University (1986) and a B.S. in Biology and Chemistry from Western Michigan University (1980).

Dr. Junker is a “Chemistry, Manufacturing and Controls” (CMC) expert and has extensive experience developing products from pre-clinical to post-marketed phases. He has managed in house and outsourced development and manufacturing activities including scale-up, transfer, validation and commercialization of processes for large and small molecule drug products. Deep understanding of cellular biochemistry, purification of proteins, small molecule drug development, formulation of drug products and analytical method development. Supported “Greenfield” and smaller facility design projects, managed capital projects for Clients including the schedule, budget, and diverse teams needed to implement Program requirements. Supported IND, NDA and BLA submissions as CMC expert with working knowledge of current FDA and European regulations for the approval of drug and biologic products.